Access the full text.
Sign up today, get DeepDyve free for 14 days.
A Fassas, VK Kimiskidis, I Sakellari (2011)
Long-term results of stem cell transplantation for MS: a single-center experience., 76
P. Muraro, D. Douek, Amy Packer, Katherine Chung, F. Guenaga, R. Cassiani-Ingoni, Catherine Campbell, S. Memon, J. Nagle, F. Hakim, R. Gress, H. McFarland, R. Burt, Roland Martin (2005)
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patientsThe Journal of Experimental Medicine, 201
A. Fassas, V. Kimiskidis, I. Sakellari, K. Kapinas, A. Anagnostopoulos, V. Tsimourtou, K. Sotirakoglou, A. Kazis (2011)
Long-term results of stem cell transplantation for MSNeurology, 76
N. Pfender, R. Saccardi, Roland Martin (2013)
Autologous Hematopoietic Stem Cell Transplantation as a Treatment Option for Aggressive Multiple SclerosisCurrent Treatment Options in Neurology, 15
(2001)
Multiple Sclerosis Functional Composite (MSFC) administration and scoring manual. National Multiple Sclerosis Society. http://main.nationalmssociety.org /docs/HOM/MSFC_Manual_and_Forms.pdf
R. Saccardi, M. Freedman, M. Sormani, H. Atkins, D. Farge, L. Griffith, G. Kraft, G. Mancardi, R. Nash, M. Pasquini, R. Martin, P. Muraro, R. Saccardi (2012)
A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paperMultiple Sclerosis (Houndmills, Basingstoke, England), 18
J. Frischer, S. Bramow, A. Dal-Bianco, C. Lucchinetti, H. Rauschka, M. Schmidbauer, H. Laursen, P. Sørensen, H. Lassmann (2009)
The relation between inflammation and neurodegeneration in multiple sclerosis brainsBrain, 132
Jacqueline Chen, D. Collins, H. Atkins, M. Freedman, A. Galal, D. Arnold (2006)
Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosisNeurology, 66
L. George (2003)
The Statistical Analysis of Failure Time DataTechnometrics, 45
F. Appelbaum, S. Forman, R. Negrin, K. Blume (2003)
Thomas' hematopoietic cell transplantation
J. Berard, M. Bowman, H. Atkins, M. Freedman, L. Walker (2014)
Cognitive fatigue in individuals with multiple sclerosis undergoing immunoablative therapy and hematopoietic stem cell transplantationJournal of the Neurological Sciences, 336
R. Burt, Y. Loh, B. Cohen, Dusan Stefosky, R. Balabanov, G. Katsamakis, Y. Oyama, Eric Russell, J. Stern, P. Muraro, J. Rose, A. Testori, J. Bucha, B. Jovanovic, F. Milanetti, J. Storek, J. Voltarelli, W. Burns (2009)
Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II studyThe Lancet Neurology, 8
A. Fassas, A. Anagnostopoulos, A. Kazis, K. Kapinas, I. Sakellari, V. Kimiskidis, A. Tsompanakou (1997)
Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot studyBone Marrow Transplantation, 20
E. Havrdová, S. Galetta, M. Hutchinson, D. Stefoski, D. Bates, C. Polman, Paul O’Connor, G. Giovannoni, J. Phillips, F. Lublin, A. Pace, R. Kim, R. Hyde (2009)
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) studyThe Lancet Neurology, 8
S. Rowley, M. Loken, J. Radich, L. Kunkle, B. Mills, T. Gooley, L. Holmberg, P. Mcsweeney, K. Beach, B. Macleod, F. Appelbaum, W. Bensinger (1998)
Isolation of CD34+ cells from blood stem cell components using the Baxter Isolex systemBone Marrow Transplantation, 21
R. Saccardi, T. Kozák, C. Bocelli-Tyndall, A. Fassas, A. Kazis, E. Havrdová, E. Carreras, A. Saiz, B. Löwenberg, P. Boekhorst, F. Gualandi, H. Openshaw, G. Longo, F. Pagliai, L. Massacesi, E. Deconink, J. Ouyang, F. Nagore, J. Besalduch, I. Lisukov, A. Bonini, E. Merelli, S. Slavin, A. Gratwohl, J. Passweg, A. Tyndall, A. Steck, M. Andolina, M. Capobianco, J. Martín, A. Lugaresi, G. Meucci, Ricardo Saez, R. Clark, Mario Fernández, L. Fouillard, B. Herstenstein, V. Koza, E. Cocco, H. Baurmann, G. Mancardi (2006)
Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party databaseMultiple Sclerosis, 12
K. Rammohan, Milissa Ortega, S. Delgado, Leticia Tornes (2011)
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosisNeurology, 77
(2010)
SIENA-based estimates of brain-volume change in a clinical-trial setting: use of an incremental-change -summation approach to evaluate different imputation methods used to estimate missing data
T. Daikeler, M. Labopin, M. Gioia, M. Abinun, T. Alexander, I. Miniati, F. Gualandi, A. Fassas, T. Martin, C. Schwarze, N. Wulffraat, M. Buch, A. Sampol, E. Carreras, B. Dubois, B. Gruhn, T. Güngör, D. Pohlreich, A. Schuerwegh, E. Snarski, J. Snowden, P. Veys, A. Fasth, S. Lenhoff, C. Messina, J. Voswinkel, M. Badoglio, J. Henes, D. Launay, A. Tyndall, E. Gluckman, D. Farge (2011)
Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party.Blood, 118 6
P. Muraro, H. Robins, Sachin Malhotra, Michael Howell, D. Phippard, C. Desmarais, Alessandra Sousa, L. Griffith, N. Lim, R. Nash, L. Turka (2014)
T cell repertoire following autologous stem cell transplantation for multiple sclerosis.The Journal of clinical investigation, 124 3
W. Mcdonald, A. Compston, G. Edan, D. Goodkin, H. Hartung, F. Lublin, H. McFarland, D. Paty, C. Polman, S. Reingold, M. Sandberg-wollheim, W. Sibley, A. Thompson, S. Noort, B. Weinshenker, J. Wolinsky (2001)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosisAnnals of Neurology, 50
J. Kurtzke (1983)
Rating neurologic impairment in multiple sclerosisNeurology, 33
J. Hobart, D. Lamping, R. Fitzpatrick, A. Riazi, A. Thompson (2001)
The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.Brain : a journal of neurology, 124 Pt 5
G. Mancardi, R. Saccardi (2008)
Autologous haematopoietic stem-cell transplantation in multiple sclerosisThe Lancet Neurology, 7
S. Reingold, J. Steiner, C. Polman, J. Cohen, M. Freedman, L. Kappos, A. Thompson, J. Wolinsky (2009)
The challenge of follow-on biologics for treatment of multiple sclerosisNeurology, 73
JF Kurtzke (1983)
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)., 33
R. Nash, James Bowen, P. Mcsweeney, S. Pavletic, K. Maravilla, Man-soo Park, J. Storek, K. Sullivan, Jinan Al-Omaishi, J. Corboy, J. Dipersio, G. Georges, T. Gooley, L. Holmberg, C. Lemaistre, K. Ryan, H. Openshaw, Julie Sunderhaus, R. Storb, J. Zunt, G. Kraft (2003)
High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.Blood, 102 7
P. Darlington, T. Touil, J. Doucet, D. Gaucher, J. Zeidan, D. Gauchat, R. Corsini, H. Kim, M. Duddy, F. Jalili, N. Arbour, Hania Kebir, Jacqueline Chen, D. Arnold, M. Bowman, J. Antel, A. Prat, M. Freedman, H. Atkins, R. Sékaly, R. Cheynier, A. Bar-Or (2013)
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantationAnnals of Neurology, 73
G. Mancardi, M. Sormani, M. Gioia, L. Vuolo, F. Gualandi, M. Amato, E. Capello, D. Currò, A. Uccelli, A. Bertolotto, C. Gasperini, A. Lugaresi, E. Merelli, G. Meucci, L. Motti, M. Tola, E. Scarpini, A. Repice, L. Massacesi, R. Saccardi (2012)
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experienceMultiple Sclerosis Journal, 18
G. Cutter, M. Baier, R. Rudick, D. Cookfair, J. Fischer, J. Petkau, K. Syndulko, B. Weinshenker, J. Antel, C. Confavreux, G. Ellison, F. Lublin, Aaron Miller, Stephen Rao, S. Reingold, A. Thompson, E. Willoughby (1999)
Development of a multiple sclerosis functional composite as a clinical trial outcome measure.Brain : a journal of neurology, 122 ( Pt 5)
R. Nash (2009)
Hematopoietic cell transplantation for autoimmune diseases, 2
J. Kalbfleisch, R. Prentice (1980)
The Statistical Analysis of Failure Time Data
M. Filippi, M. Rocca, D. Arnold, R. Bakshi, F. Barkhof, N. Stefano, F. Fazekas, E. Frohman, J. Wolinsky (2006)
EFNS guidelines on the use of neuroimaging in the management of multiple sclerosisEuropean Journal of Neurology, 13
H. Atkins, M. Freedman (2012)
Hematopoietic Stem Cell Therapy for Multiple Sclerosis: Top 10 Lessons LearnedNeurotherapeutics, 10
A. Turner, Rhonda Williams, J. Bowen, D. Kivlahan, J. Haselkorn (2006)
Suicidal ideation in multiple sclerosis.Archives of physical medicine and rehabilitation, 87 8
A. Sadovnick, K. Eisen, G. Ebers, D. Paty (1991)
Cause of death in patients attending multiple sclerosis clinicsNeurology, 41
A. Coles, C. Twyman, D. Arnold, Jeffrey Cohen, C. Confavreux, E. Fox, H. Hartung, E. Havrdová, K. Selmaj, H. Weiner, T. Miller, E. Fisher, R. Sandbrink, R. Sandbrink, S. Lake, D. Margolin, P. Oyuela, M. Panzara, D. Compston (2012)
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialThe Lancet, 380
ImportanceMost patients with relapsing-remitting (RR) multiple sclerosis (MS) who receive approved disease-modifying therapies experience breakthrough disease and accumulate neurologic disability. High-dose immunosuppressive therapy (HDIT) with autologous hematopoietic cell transplant (HCT) may, in contrast, induce sustained remissions in early MS. ObjectiveTo evaluate the safety, efficacy, and durability of MS disease stabilization through 3 years after HDIT/HCT. Design, Setting, and ParticipantsHematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS) is an ongoing, multicenter, single-arm, phase 2 clinical trial of HDIT/HCT for patients with RRMS who experienced relapses with loss of neurologic function while receiving disease-modifying therapies during the 18 months before enrolling. Participants are evaluated through 5 years after HCT. This report is a prespecified, 3-year interim analysis of the trial. Thirty-six patients with RRMS from referral centers were screened; 25 were enrolled. InterventionsAutologous peripheral blood stem cell grafts were CD34+ selected; the participants then received high-dose treatment with carmustine, etoposide, cytarabine, and melphalan as well as rabbit antithymocyte globulin before autologous HCT. Main Outcomes and MeasuresThe primary end point of HALT-MS is event-free survival defined as survival without death or disease activity from any one of the following outcomes: (1) confirmed loss of neurologic function, (2) clinical relapse, or (3) new lesions observed on magnetic resonance imaging. Toxic effects are reported using National Cancer Institute Common Terminology Criteria for Adverse Events. ResultsGrafts were collected from 25 patients, and 24 of these individuals received HDIT/HCT. The median follow-up period was 186 weeks (interquartile range, 176-250) weeks). Overall event-free survival was 78.4% (90% CI, 60.1%-89.0%) at 3 years. Progression-free survival and clinical relapse-free survival were 90.9% (90% CI, 73.7%-97.1%) and 86.3% (90% CI, 68.1%-94.5%), respectively, at 3 years. Adverse events were consistent with expected toxic effects associated with HDIT/HCT, and no acute treatment-related neurologic adverse events were observed. Improvements were noted in neurologic disability, quality-of-life, and functional scores. Conclusions and RelevanceAt 3 years, HDIT/HCT without maintenance therapy was effective for inducing sustained remission of active RRMS and was associated with improvements in neurologic function. Treatment was associated with few serious early complications or unexpected adverse events.
JAMA Neurology – American Medical Association
Published: Feb 1, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.